ItHome Cardiac Arrest Bivalirudin bests heparin for treating heart attack patients undergoing PCI

Bivalirudin bests heparin for treating heart attack patients undergoing PCI

Credits to the 👉🏾Source Link👉🏾 Olivia
Bivalirudin bests heparin for treating heart attack patients undergoing PCI

Overall, the team noted, the two medications had similar rates of 30-day mortality—1.9% for bivalirudin and 2.1% for heparin. When it came to serious bleeding events, however, the rates were 3.4% for bivalirudin and 5.7% for heparin.

“This individual patient data pooled analysis aimed to determine the optimal anticoagulant to be used during PCI in patients with AMI,” lead author Gregg W. Stone, MD, a professor of medicine at the Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai, said in a statement detailing the findings.

Stone did note that bivalirudin was linked to “increased rates of myocardial infarction and stent thrombosis compared to heparin,” but a high-dose infusion of bivalirudin following PCI “mitigated the MI and stent thrombosis risk.”

The study was funded by the Cardiovascular Research Foundation, the nonprofit organization behind TCTMD, and The Medicines Company.

More information on TCT Connect 2020 is available here.

Source Link

related posts

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: